Why This Beaten-Down GLP-1 Stock Could Be a Steal

Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize on the trend.One smaller company that's also in the race is Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech. Its stock has performed poorly this year, but some of the reasons behind the decline are somewhat unjustified.The market may be underestimating the biotech's potential, and the stock could have significant upside from its current levels. Here's why Viking could be a steal right now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool